{"id":"W4382807504","doi":"10.1016/j.annonc.2023.04.017","title":"O-2 Phase III study of NUC-1031 + cisplatin vs gemcitabine + cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121)","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Janssen Biotech; Genentech; Natera; National Institutes of Health; Daiichi Sankyo Europe; National Cancer Institute; Servier; Astellas Pharma; Eisai; Pfizer; Incyte; Seagen; Plexxikon; Array BioPharma; Parker Institute for Cancer Immunotherapy; Ipsen; Mirati Therapeutics; AstraZeneca; Novocure; Sanofi; Amgen; Celgene; Bristol-Myers Squibb; Eli Lilly and Company; Agios Pharmaceuticals","keywords":"Gemcitabine; Medicine; Gallbladder cancer; Cisplatin; Interim analysis; Internal medicine; Gallbladder; Biliary tract cancer; Phases of clinical research; Oncology; Population; Biliary tract; Clinical endpoint; Chemotherapy; Gastroenterology; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001823333,0.001787848,0.003173803,0.000565249,0.0005239227,0.001413351,0.001566919,0.001577983,0.007890831],"category_scores_gemma":[0.001267039,0.000910704,0.002559731,0.0006015868,0.001123986,0.00116732,0.0005402209,0.004537861,0.001416847],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001421828,"about_ca_system_score_gemma":0.002710382,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003879915,"about_ca_topic_score_gemma":0.01227189,"domain_scores_codex":[0.999488,0.0002844342,0.00002086976,0.00007581559,0.00003492821,0.00009595173],"domain_scores_gemma":[0.9989982,0.0001728974,0.0001620733,0.00008079908,0.00005349311,0.0005324853],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9324737,0.03007709,0.001636289,0.0004791675,0.001080065,0.00004913054,0.0001194577,0.001029072,0.006268059,0.0002138704,0.002218883,0.02435523],"study_design_scores_gemma":[0.7956339,0.1972279,0.003736039,0.00002694454,0.0005798591,0.00006042636,0.0000533907,0.0005311953,0.0007215809,0.0001292466,0.001277788,0.00002177329],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9856632,0.002316099,0.0005332094,0.0008414561,0.0004045749,0.003525324,0.002992521,0.0001296212,0.003593921],"genre_scores_gemma":[0.9698927,0.004707216,0.003039601,0.00184029,0.0004977181,0.004488711,0.00591336,0.0001216961,0.009498696],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007890831,"threshold_uncertainty_score":0.02639741,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09294583844716976,"score_gpt":0.4138732135633043,"score_spread":0.3209273751161345,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}